Researchers from the SWOG Cancer Research Network used methylation patterns in cell-free DNA extracted from blood samples to predict which patients with muscle-invasive bladder cancer were likely to benefit from chemotherapy before their surgery.
Pfizer Inc. on April 26 announced results from the pivotal phase III CREST trial of sasanlimab, an investigational anti-PD-1 monoclonal antibody, in combination with standard-of-care Bacillus Calmette-Guérin as induction therapy with or without maintenance in patients with BCG-naïve, high-risk non-muscle invasive bladder cancer.
